All In Biotech

BLA 761090 · Dyax Corp.

Takhzyro

Lanadelumab-Flyo · Subcutaneous · Plasma Kallikrein Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 23, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

20

9 Phase 3, 1 recruiting

FAERS reports

3,228

1,536 serious, 41 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2026.

TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. ( 1 )

Mechanism: Lanadelumab-flyo is a fully human monoclonal antibody (IgG1/κ-light chain) that binds plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 3, 2023 Supplement 10 · Efficacy · priority review OrphanLetterLabel
  • Aug 23, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • TAKHZYRO · LANADELUMAB-FLYO 300MG/2ML (150MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • TAKHZYRO · LANADELUMAB-FLYO 300MG/2ML (150MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lanadelumab" as an intervention, any sponsor and status, largest first.

All 20 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hereditary angioedema1,217
  • drug ineffective298
  • product dose omission issue265
  • weight increased245
  • weight decreased238
  • headache188
  • condition aggravated187
  • inappropriate schedule of product administration169
  • product use issue161
  • intentional product use issue157
  • injection site pain143
  • stress143

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20154
20162
20175
2018106
2019393
2020318
2021291
2022325
2023374
2024474
2025563
2026373

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Takhzyro (Lanadelumab-Flyo)

2024 spending

$223M

Beneficiaries

512

4,752 claims

Per beneficiary

$435,556

$12,775.31 per unit

View as table
YearSpending
2020$151,333,291
2021$174,024,500
2022$192,066,440
2023$194,367,297
2024$223,004,903

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Dyax Corp.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.